Phase 1/2 Study of SBRT With or Without GC4711 for NSCLC
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
GTI-4711-101 is a Phase 1-2 study of the safety of GC4711, and its potential to reduce
radiation-related pulmonary injury due to SBRT for early stage large or central localized
NSCLC. After an open-label, Phase 1, safety cohort of approximately 5 subjects has been
completed, a randomized, double-blind, placebo-controlled Phase 2 portion will be conducted.